Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01460641 · ClinicalTrials.gov registry record
Perfusion CT as a Predictor of Treatment Response in Patients With Rectal Cancer
A clinical trial, sponsored by Stanford University.
- Completed
- Registry status
- 21
- Enrollment target
NCT01460641: Completed study, sponsored by Stanford University.
NCT01460641 is a clinical trial that has completed, run by Stanford University. The registered enrollment target is 21 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01460641 has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- 21 participants
- Enrollment target
Study Summary
A research study of rectal cancer perfusion (how blood flows to the rectum over time). We hope to learn whether perfusion characteristics of rectal masses may be predictive of response to treatment and whether rectal perfusion characteristics can be used to follow response to treatment.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2011-11 |
| Est. Completion | 2018-07 |
What the finished NCT01460641 record still lists
NCT01460641 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 21 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT01460641 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01460641 about?
NCT01460641 is a clinical study titled "Perfusion CT as a Predictor of Treatment Response in Patients With Rectal Cancer". A research study of rectal cancer perfusion (how blood flows to the rectum over time). We hope to learn whether perfusion characteristics of rectal masses may be predictive of response to treatment and whether rectal perfusion characteristics can be used to follow response to treatment.
What is the current status of trial NCT01460641?
This trial is currently completed. The enrollment target is 21 participants. The study started on 2011-11. Estimated completion is 2018-07.
Who is sponsoring clinical trial NCT01460641?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia